Kythera Biopharmaceuticals to price initial public offering of stock

JPMorgan, Goldman Sachs, Leerink Swann and Lazard Capital assist

By Devika Patel

Knoxville, Tenn., May 17 - Kythera Biopharmaceuticals, Inc. will price an initial public offering of its common stock, according to a Form S-1 filed Thursday with the Securities and Exchange Commission. The company expects its shares will trade on the Nasdaq under the symbol "KYTH."

The deal has a 30-day greenshoe.

JPMorgan, Goldman Sachs & Co., Leerink Swann and Lazard Capital Markets are the underwriters.

Proceeds will be used for phase 3 clinical trials of ATX-101, working capital and general corporate purposes, including research and development.

The biopharmaceutical company is based in Calabasas, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.